Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLA2001 Safety and Immunogenicity in Healthy Adults for COVID-19
NCT04671017Phase 2Completed
- Sponsor
- Valneva
- Start
- Dec 2020
- Primary completion
- Feb 2021
- Modality
- Viral Vector Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of VLA2001 in coronavirus disease 2019 (COVID-19), sponsored by Valneva. Started Dec 2020; status: completed.
02
Drugs
VLA2001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04671017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04671017.